Kenvue (KVUE) Q3 2025 10-Q Quarterly Report
Filed: Nov 3, 2025Period ending Sep 28, 2025
Health Care
Perfumes, Cosmetics & Other Toilet PreparationsSEC EDGAR Kenvue (KVUE) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 3, 2025 for the fiscal period ending Sep 28, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Kenvue Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • Quarterly revenue $3.76B, down 3.5% YoY ($135M decrease from $3.9B)
- • Gross profit margin up 59.1% vs 58.5% YoY; operating income down 3.8%
Risk Factors
- • Newly added risk: Transaction financing increasing K-C’s debt, potentially reducing liquidity and flexibility before closing
- • Most materially updated risk: $1,136M termination fee added if Transaction terminated under certain conditions, increasing financial exposure
Kenvue Q3 2025 Quarterly FinancialsXBRL
Revenue
$3.8B
▼ -3.5% YoY▼ -2.0% QoQ
Net Income
$398M
▲ +3.9% YoY▼ -5.2% QoQ
Net Margin
10.6%
▲ +75bp YoY▼ -37bp QoQ
Source: XBRL data from Kenvue Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Kenvue Quarterly Reports
Get deeper insights on Kenvue
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.